Multi-target-directed design, syntheses, and characterization of fluorescent bisphosphonate derivatives as multifunctional enzyme inhibitors in mevalonate pathway

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 6, 2013, Pages 3635-3642

  Gao, Jinbo ^b   Liu, Jinggong ^a   Qiu, Yongge ^b   Chu, Xiusheng ^b   Qiao, Yuqin ^b   Li, Ding ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bisphosphonate; Farnesyl pyrophosphate synthase; Mevalonate 5 diphosphate decarboxylase; Mevalonate kinase; Multifunctional inhibitor; Phosphomevalonate kinase

Indexed keywords

2 (15 CARBOXY 15 FLUORO 14 HYDROXY 2,6,14 TRIMETHYL 9,9 DIPHOSPHONOPENTADECA 2,6 DIENYLAMINO)BENZOIC ACID; 2 (15 CARBOXY 15,15 DIFLUORO 14 HYDROXY 2,6,14 TRIMETHYL 9,9 DIPHOSPHONOPENTADECA 2,6 DIENYLAMINO)BENZOIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBOXYLYASE; DIPHOSPHOMEVALONATE DECARBOXYLASE; ENZYME INHIBITOR; GERANYLTRANSFERASE; MEVALONATE KINASE; PHOSPHOMEVALONATE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG BINDING SITE; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFECT; DRUG SYNTHESIS; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME SYNTHESIS; FLUORESCENCE MICROSCOPY; IC 50; MOLECULAR CLONING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; DIPHOSPHONATES; ENZYME INHIBITORS; FLUORESCENT DYES; HYPERCHOLESTEROLEMIA; MEVALONIC ACID; MOLECULAR DOCKING SIMULATION; NEOPLASMS; RATS;

EUKARYOTA;

EID: 84875973434     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.02.011     Document Type: Article

References (34)

1. I. Buhaescu, and H. Izzedine Mevalonate pathway: a review of clinical and therapeutical implications Clin. Biochem. 40 2007 575 584
2. W.A. Freed-Pastor, H. Mizuno, X. Zhao, A. Langerod, S.H. Moon, R. Rodriguez-Barrueco, A. Barsotti, A. Chicas, W.C. Li, A. Polotskaia, M.J. Bissell, T.F. Osborne, B. Tian, S.W. Lowe, J.M. Silva, A.L. Borresen-Dale, A.J. Levine, J. Bargonetti, and C. Prives Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway Cell 148 2012 244 258
3. K.M. Swanson, and R.J. Hohl Anti-cancer therapy: targeting the mevalonate pathway Curr. Cancer Drug Targets 6 2006 15 37
4. E. Oldfield Targeting isoprenoid biosynthesis for drug discovery: bench to bedside Acc. Chem. Res. 43 2010 1216 1226
5. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425
6. K.L. Kavanagh, K. Guo, J.E. Dunford, X. Wu, S. Knapp, F.H. Ebetino, M.J. Rogers, R.G.G. Russell, and U. Oppermann The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc. Natl. Acad. Sci. 103 2006 7829 7834
7. A.J. Brown Cholesterol, statins and cancer Clin. Exp. Pharmacol. Physiol. 34 2007 135 141
8. Y.S. Lin, J. Park, J.W. De Schutter, X.F. Huang, A.M. Berghuis, M. Sebag, and Y.S. Tsantrizos Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells J. Med. Chem. 55 2012 3201 3215
9. Y. Qiao, J. Gao, Y. Qiu, L. Wu, F. Guo, K.K. Lo, and D. Li Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I Eur. J. Med. Chem. 46 2011 2264 2273
10. C. Bolego, R. Baetta, S. Bellosta, A. Corsini, and R. Paoletti Safety considerations for statins Curr. Opin. Lipidol. 13 2002 637 644
11. J. Armitage The safety of statins in clinical practice Lancet 370 2007 1781 1790
12. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins Circulation 109 2004 III-50 III-57
13. L.K. Bachrach, and L.M. Ward Clinical review: bisphosphonate use in childhood osteoporosis J. Clin. Endocrinol. Metab. 94 2009 400 409
14. J. Brown, and M. Zacharin Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis J. Pediatr. Endocrinol. Metab. 22 2009 55 64
15. J. Ichikawa, E. Sato, H. Haro, T. Ando, S. Maekawa, and Y. Hamada Successful treatment of SAPHO syndrome with an oral bisphosphonate Rheumatol. Int. 29 2009 713 715
16. N.B. Watts Treatment of osteoporosis with bisphosphonates Endocrinol. Metab. Clin. 27 1998 419 439
17. F. Fulfaro, A. Casuccio, C. Ticozzi, and C. Ripamonti The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials Pain 78 1998 157 169
18. M.A. Maalouf, A.J. Wiemer, C.H. Kuder, R.J. Hohl, and D.F. Wiemer Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation Bioorg. Med. Chem. 15 2007 1959 1966
19. A.P.C. Chen, Y.H. Chen, H.P. Liu, Y.C. Li, C.T. Chen, and P.H. Liang Synthesis and application of a fluorescent substrate analogue to study ligand interactions for undecaprenyl pyrophosphate synthase J. Am. Chem. Soc. 124 2002 15217 15224
20. J. Gao, X. Chu, Y. Qiu, L. Wu, Y. Qiao, J. Wu, and D. Li Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway Chem. Commun. 46 2010 5340 5342
21. Y. Qiu, and D. Li Inhibition of mevalonate 5-diphosphate decarboxylase by fluorinated substrate analogs Biochim. Biophys. Acta 1760 2006 1080 1087
22. X. Chu, and D. Li Cloning, expression, and purification of His-tagged rat mevalonate kinase Protein Expression Purif. 27 2003 165 170
23. A.E. Schulte, R. van der Heijden, and R. Verpoorte Microplate enzyme-coupled assays of mevalonate and phosphomevalonate kinase from Catharanthus roseus suspension cultured cells Anal. Biochem. 269 1999 245 254
24. G. Bansal, J.E.I. Wright, C. Kucharski, and H. Uludag A dendritic tetra(bisphosphonic acid) for improved targeting of proteins to bone Angew. Chem. Int. Ed. 44 2005 3710 3714
25. M.K. Kim, T.S. Kleckley, A.J. Wiemer, S.A. Holstein, R.J. Hohl, and D.F. Wiemer Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues J. Org. Chem. 69 2004 8186 8193
26. J. Eyzaguirre, D. Valdebenito, and E. Cardemil Pig liver phosphomevalonate kinase: kinetic mechanism Arch. Biochem. Biophys. 454 2006 189 196
27. B.T. Burlingham, and T.S. Widlanski An intuitive look at the relationship of Ki and IC50: a more general use for the Dixon plot J. Chem. Educ. 80 2003 214
28. A.J. Roelofs, K. Thompson, S. Gordon, and M.J. Rogers Molecular mechanisms of action of bisphosphonates: current status Clin. Cancer Res. 12 2006 6222s 6230s
29. J.H. Mao, S. Mukherjee, Y. Zhang, R. Cao, J.M. Sanders, Y.C. Song, Y.H. Zhang, G.A. Meints, Y.G. Gao, D. Mukkamala, M.P. Hudock, and E. Oldfield Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes J. Am. Chem. Soc. 128 2006 14485 14497
30. J. Body, R. Bartl, P. Burckhardt, P. Delmas, I. Diel, H. Fleisch, J. Kanis, R. Kyle, G. Mundy, and A. Paterson Current use of bisphosphonates in oncology. International bone and cancer study group J. Clin. Oncol. 16 1998 3890 3899
31. R. Coleman Bisphosphonates in breast cancer Ann. Oncol. 16 2005 687 695
32. J.R. Green Antitumor effects of bisphosphonates Cancer 97 2003 840 847
33. H. Neville-Webbe, I. Holen, and R. Coleman The anti-tumour activity of bisphosphonates Cancer Treat. Rev. 28 2002 305 319
34. D. Mukkamala, J.H. No, L.M. Cass, T.K. Chang, and E. Oldfield Bisphosphonate inhibition of a plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data J. Med. Chem. 51 2008 7827 7833